

## MIT Open Access Articles

*Efficient embryonic homozygous gene conversion  
via RAD51-enhanced interhomolog repair*

The MIT Faculty has made this article openly available. **Please share**  
how this access benefits you. Your story matters.

**Citation:** Wilde, Jonathan J, Aida, Tomomi, del Rosario, Ricardo CH, Kaiser, Tobias, Qi, Peimin et al. 2021. "Efficient embryonic homozygous gene conversion via RAD51-enhanced interhomolog repair." Cell, 184 (12).

**As Published:** 10.1016/J.CELL.2021.04.035

**Publisher:** Elsevier BV

**Persistent URL:** <https://hdl.handle.net/1721.1/143451>

**Version:** Author's final manuscript: final author's manuscript post peer review, without publisher's formatting or copy editing

**Terms of use:** Creative Commons Attribution-NonCommercial-NoDerivs License





Published in final edited form as:

Cell. 2021 June 10; 184(12): 3267–3280.e18. doi:10.1016/j.cell.2021.04.035.

## Efficient Embryonic Homozygous Gene Conversion via RAD51-Enhanced Interhomolog Repair

Jonathan J. Wilde<sup>1,3,\*</sup>, Tomomi Aida<sup>1,3</sup>, Ricardo C.H. del Rosario<sup>2</sup>, Tobias Kaiser<sup>1</sup>, Peimin Qi<sup>1</sup>, Martin Wienisch<sup>1</sup>, Qiangge Zhang<sup>1</sup>, Steven Colvin<sup>1</sup>, Guoping Feng<sup>1,2,4,\*</sup>

<sup>1</sup>Department of Brain & Cognitive Sciences; McGovern Institute for Brain Research, Massachusetts Institute of Technology (MIT); Cambridge, Massachusetts 02139; USA

<sup>2</sup>Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard; Cambridge, Massachusetts 02142; USA

<sup>3</sup>These authors contributed equally.

<sup>4</sup>Lead Contact

### Summary

Searching for factors to improve knock-in efficiency for therapeutic applications, biotechnology, and generation of non-human primate (NHP) models of disease, we found that the strand exchange protein RAD51 can significantly increase Cas9-mediated homozygous knock-in in mouse embryos through an interhomolog repair (IHR) mechanism. IHR a hallmark of meiosis, but only occurs at low frequencies in somatic cells and its occurrence in zygotes is controversial. Using multiple approaches, we provide evidence for an endogenous IHR mechanism in the early embryo that can be enhanced by RAD51. This process can be harnessed to generate homozygotes from wildtype zygotes using exogenous donors and to convert heterozygous alleles into homozygous alleles without exogenous templates. Furthermore, we identify additional IHR-promoting factors and describe features of IHR events. Together, our findings show conclusive evidence for IHR in mouse embryos and describe an efficient method for enhanced gene conversion.

### In Brief:

Genes of mouse embryos can be efficiently edited by enhancing interhomolog repair via co-injection of RAD51 with Cas9.

### Graphical Abstract

\*Correspondence: wildej@mit.edu (J.J.W.), fengg@mit.edu (G.F).


#### Author Contributions

J.J.W., T.A., M.W., Q.Z., and G.F. designed experiments. J.J.W., T.A., T.K., S.C., and P.Q. performed experiments. J.J.W., T.A., and R.C.H.R. analyzed data. J.J.W., T.A., R.C.H.R., and G.F. prepared the manuscript. G.F. supervised the project.

#### Declaration of Interests

MIT and J.J.W., T.A., M.W., Q.Z. and G.F. have submitted a patent application (U.S. Patent Application No.: 16/260,630) related to the use of enhanced interhomolog repair for gene editing purposes.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



## Introduction

CRISPR-associated (Cas) proteins and other targeted nucleases have revolutionized our ability to manipulate the genome, but the precise knock-in of exogenous DNA at targeted double-strand breaks can still be difficult. Successful knock-in requires both efficient cutting by a targeted endonuclease and recruitment of endogenous DNA repair factors to incorporate the desired edit into the host genome. However, while numerous improvements in our ability to make targeted breaks in the genome have been made, our current understanding of how to leverage endogenous DNA repair proteins to promote successful knock-in is still incomplete.

Attempts to enhance knock-in efficiency have primarily focused on three distinct approaches: inhibition of non-homologous end-joining, promotion of end resection, and enhancement of homology search and strand exchange. While methods for suppressing NHEJ through inhibition of the NHEJ-promoting protein 53BP1 have yielded promising results (Canny et al., 2018; Jayavaradhan et al., 2019), the mechanism and its direct effect on homologous recombination remains unclear. Additional methods to promote end resection, which is thought to be a definitive step toward homologous recombination, have given modest results (Charpentier et al., 2018; Nakade et al., 2018; Tran et al., 2019) and suggest a need to target additional molecules and deepen our understanding of end resection and its consequences.

Given the potential dangers of NHEJ inhibition and our poor understanding of end-resection and its ability to promote HR, directly targeting the homologous recombination machinery is an appealing method for enhancing knock-in. In 2016, a study in rabbit embryos demonstrated significant enhancement of knock-in using RS-1, a chemical agonist of the strand-exchange factor RAD51 (Song et al., 2016), a strand exchange protein critical for HR. In cells lacking DNA damage, RAD51 forms small, enzymatically inactive heptameric rings (Yu et al., 2003). In response to double-strand breaks (DSBs), the protein BCCIP promotes BRCA2-mediated disruption of RAD51 self-association, allowing RAD51 recruitment to resected DSBs (Lu et al., 2005). RAD51 then forms long nucleofilaments on single-stranded overhangs produced by end resection and actively performs the homology search and strand invasion steps that are the basis of homologous recombination (Krejčí et al., 2012). Reinforcing the central role of RAD51 in HR and knock-in events following targeted double-strand breaks, fusion of RAD51 to Cas9, which has a dominant-negative effect on endogenous RAD51 function, inhibits HDR (Rees et al., 2019).

Based on the aforementioned findings and the key role of RAD51 in homologous recombination we sought to further explore the utility of RAD51 for Cas9-based knock-in events. Unexpectedly, we find that RAD51 can increase homozygosity without any effects on initial knock-in efficiency through enhancement of interhomolog repair (IHR). After demonstrating increased homozygosity in knock-in experiments using single-strand oligonucleotide donors, we demonstrate frequent homozygous conversion at multiple sites on different chromosomes without the use of donor DNA templates. We then identify additional factors that can enhance IHR, including a RAD51 variant capable of nearly indel-free IHR, and describe mechanistic properties of IHR events. In summary, our study provides conclusive evidence of IHR in the early mouse embryo and shows that RAD51 and homologous recombination-associated factors can be used to enhance the process for efficient homozygous knock-in and template-free conversion of heterozygous alleles to homozygous alleles.

## Results

### Co-Injection of RAD51 with Cas9 RNPs Enhances Homozygous Knock-in

Based on our previous success using recombinant Cas9 ribonucleoproteins (RNPs) to enhance HDR in mouse embryos (Aida et al., 2015; Quadros et al., 2017) and the reported enhancement of HDR by the RAD51 agonist RS-1, we began by testing whether recombinant RAD51 could efficiently stimulate knock-in of an autism-associated point mutation in *Chd2* (c.5051G>A; R1685H in human, R1684H in mouse; hereon referred to as *Chd2<sup>RH</sup>*; Figure 1A). Previous studies have shown that KI efficiency is affected by the proximity of the Cas9 cut site to the insertion site (Paquet et al., 2016), so we chose a guide positioned where the cut site is directly adjacent to the desired G>A point mutation. We performed both pronuclear (PNI) and cytoplasmic (CPI) injections of RNPs containing crRNA, tracrRNA, and SpyCas9 along with a single-stranded DNA donor (30 ng/μL for PNI and 100 ng/μL for CPI) and RAD51 (10 ng/μL) in mouse zygotes and observed overall KI efficiencies of 78% (7/9) and 56% (5/9) for CPI and PNI, respectively (Figure 1B,C). Both CPI and PNI resulted in high homozygous KI efficiencies of 71% and 100% for CPI- and

PNI-derived KI embryos, respectively (Figure 1D) and on-target editing was confirmed with primers sitting outside of the donor template. We further confirmed homozygosity by breeding putative homozygotes with wild-type mice and genotyping the resulting F<sub>1</sub> pups, which found that 100% (36/36) of animals from 6 successful mating pairs had a *Chd2*<sup>RH/+</sup> genotype (Figure 1E).

Since we did not initially generate *Chd2*<sup>RH</sup> mice from injections lacking RAD51, we performed injections to directly test the impact of RAD51 on KI efficiency at the *Chd2*<sup>RH</sup> locus. Since we did not observe differences in editing efficiency or homozygosity rates between CPI and PNI (Figures 1C and 1D and Table S1), we utilized PNI for the rest of this study, as this is our standard approach for generating mouse models. Pronuclear injection was performed with or without recombinant RAD51 and embryos were cultured for 2–3 days until the morula or blastocyst stage before DNA purification and nested PCR for genotyping. Sanger sequencing showed that RAD51 only slightly increased overall knock-in efficiency (Figure 2A, left), but strongly increased homozygous knock-in efficiency (Figure 2A, middle, right). To test whether the observed effects of RAD51 were locus-dependent, we used the same strategy to knock in an albinism-associated mutation (c.265T>A; C89S; hereon referred to as *Tyr*<sup>C89S</sup>; schematic in Figure 2B) in tyrosinase (*Tyr*), the rate-limiting enzyme in melanin production (Ghodsinejad Kalahroudi et al., 2014). Homozygous disruption of *Tyr* results in mice completely lacking pigment (Figure 2C), but because homozygous indels or compound disruption of *Tyr* can result in albinism, all F<sub>0</sub> animals were genotyped (Figure 2D) and phenotyped (Table S1) to assess the effects of RAD51 on knock-in efficiency. In pups with visible mosaic albinism, genotyping was performed using samples from tissue completely lacking melanin to assess the number of animals with at least one homozygous KI event (Figure 2E, middle). Injections without RAD51 showed a high overall KI efficiency that was not significantly increased by the addition of RAD51 (Figure 2E, left), but sequencing found that RAD51 significantly enhanced homozygous KI efficiency, with 44% of pups (including mosaics) having an albino phenotype resulting from homozygous KI of the *Tyr*<sup>C89S</sup> allele with RAD51, as compared to only 12% without (Figure 2E, middle). Furthermore, RAD51 co-injection increased the rate of pure, non-mosaic homozygous knock-in (Figure 2E, right). Together, these data demonstrate that RAD51 can increase homozygous knock-in rates.

We were intrigued to see that RAD51 co-injection more than doubled the observed homozygosity at both the *Chd2* and *Tyr* loci, regardless of whether or not we took mosaicism into account (Figure 2A,E). At the onset of this study, previous attempts to increase HDR through pharmacological or genetic mechanisms had not shown such high homozygosity rates (Maruyama et al., 2015; Paquet et al., 2016; Takayama et al., 2017), leading us to investigate the mechanism by which RAD51 can promote such an outcome. Our findings that RAD51 did not increase overall knock-in efficiency (Figure 2A,E) agree with more recent work showing that RAD51 is not required for single-stranded template repair (SSTR) (Richardson et al., 2018) and therefore suggest that RAD51-mediated effects on homozygosity do not arise from the stimulation of independent knock-in events on both alleles. Additionally, we found it surprising that we observed multiple embryos from both *Chd2*<sup>RH</sup> and *Tyr*<sup>C89S</sup> injections whose genotyping results suggested the presence of the same indel on both alleles (Figure S1 and Table S1). Genotyping of F<sub>1</sub> pups derived from a *Chd2*-

targeted female with such a homozygous indel revealed that all pups were heterozygous for the same indel, confirming homozygosity of the founder (Figure S1). Although we could not completely rule out that these deletions resulted from stereotyped generation of the same indel on both alleles or microhomology-mediated end-joining (MMEJ) (Aida et al., 2016; McVey and Lee, 2008), the variety of observed indels and lack of corresponding MMEJ sequence motifs suggest that the homozygosity could have arisen from direct transfer of genetic information between homologous chromosomes.

### **RAD51 Promotes Interhomolog Repair in the Early Embryo**

More than 20 years ago, experiments in mouse ES cells found evidence of recombination events between homologous chromosomes (Moynahan and Jasin, 1997; Richardson et al., 1998). While these IHR events are common and well-understood in meiotic cells, their occurrence in mitotic cell types is poorly described. In light of several recent studies that have described embryonic IHR after the induction of a targeted double-strand break (DSB) by Cas9 (Ma et al., 2017; Wu et al., 2013), we hypothesized that RAD51 can promote homozygosity through the same mechanism. To directly test this, we attempted to generate *Chd2<sup>RH/RH</sup>* embryos from *Chd2<sup>RH/+</sup>* embryos without the use of an exogenous donor template. To do this, we generated *Chd2<sup>RH/+</sup>* zygotes by *in vitro* fertilization of wild-type oocytes with sperm from *Chd2<sup>RH/RH</sup>* donors and then specifically targeted the wild-type maternal allele with Cas9. It should be noted that this strategy rules out the possibility of false-positive results from parthenogenetic embryos, as the mutant allele to be copied is carried by the sperm. As illustrated in Figure 3A, PNI was performed on zygotes ~8 hours post fertilization (hpf) using an RNP mixture of crRNA, tracrRNA, and SpyCas9 with or without RAD51. The *Chd2<sup>RH</sup>* allele contains mutations in both the protospacer and its associated PAM and we confirmed through an *in vitro* digestion assay that Cas9 is only capable of cutting the wild-type maternal allele (Figure S2). Consistent with the rates observed in previous work (Ma et al., 2017; Wu et al., 2013), we saw IHR events in 26% of control-injected embryos, including mosaics (Figure 3B,C). Co-injection of RAD51 significantly increased this rate to 74% (Figure 3C, left). We also observed a similar increase in pure, non-mosaic IHR rates in RAD51-injected embryos (Figure 3C, right), supporting the hypothesis that RAD51 can promote IHR in mouse embryos.

To validate our Sanger sequencing-based genotyping strategy, we performed an independent set of injections with Cas9 and RAD51 using the same strategy described in Figure 3, then split the DNA from the lysed embryos into two aliquots and used one aliquot for nested PCR and Sanger sequencing and the second aliquot for an independent nested PCR reaction and NGS-based amplicon sequencing (see STAR Methods). Because this strategy uses unique sets of PCR primers for amplification of two pools of DNA from the same embryo, the likelihood of false-positives due to PCR bias or allele dropout is greatly decreased. After analyzing the Sanger sequencing traces, we chose a batch of embryos with different *RH* allele levels to analyze by amplicon sequencing. Comparison of the Sanger and amplicon sequencing results demonstrated a high correlation of the *RH* allele percentage derived from the two methods ( $r^2=0.9672$ ; Figure S2, Table S2), validating the accuracy of our Sanger-based analysis strategy and our findings of both endogenous and enhanced IHR rates at the *Chd2* locus.



Comprehensive studies of indel properties in single sgRNA-based CRISPR studies have found indels large enough to disrupt our genotyping strategy (>250bp in either direction), but show that they are too infrequent to account for the observed rates of homozygosity in our experiments (Adikusuma et al., 2018; Kosicki et al., 2018; Shin et al., 2017). Nonetheless, we performed multiple experiments to directly rule out the possibility of widespread false positives resulting from large deletions on the Cas-targeted maternal allele. First, we developed and performed a multiplex genomic qPCR assay to analyze copy number at the target locus (see STAR Methods). To confirm that our method was capable of identifying large heterozygous deletions in *Chd2*, we generated a mouse line carrying a 1630bp deletion encompassing the *RH1* locus (Figure S2) and performed genomic qPCR on DNA extracted from embryos generated by IVF with either a wild-type or homozygous mutant sperm donor. Analysis of normalized DNA content at the *Chd2* locus in embryos heterozygous for the deletion confirmed our assay's ability to identify heterozygous genomic deletions (Figure 3D). Using this qPCR strategy, we were able to confirm a normal copy number at the *Chd2* locus in 10/10 randomly selected pure homozygous mutants (Figure 3D). Next, in an attempt to more definitively rule out large heterozygous deletions, we generated pups using the IVF strategy described in Figure 3A (including RAD51), identified potential pure homozygotes, and crossed them with wild-type mice to generate F<sub>1</sub> offspring. Genotyping of F<sub>1</sub> animals confirmed that 100% were heterozygous for the R1684H mutation (Figure 3E), proving that the F<sub>0</sub> animals were true homozygotes generated by interhomolog repair. Thus, our results strongly support the conclusion that interhomolog repair occurs in the early mouse embryo and that RAD51 is capable of enhancing this process.

### **RAD51 Localizes to Cas9-targeted Regions in the Zygote**

After fertilization, the maternal and paternal genomes remain physically separated in their own pronuclei until the completion of S-phase, at which time the nuclear envelopes break down in preparation for mitosis. This poses a significant hurdle to IHR in the zygote and has led researchers to question whether zygotic IHR is possible, given that it requires direct physical interaction between maternal and paternal homologs (Egli et al., 2018). Because alleles harboring an unresolved DSB cannot be amplified by PCR, accurate genotyping of one-cell embryos is not possible and thus, we chose to investigate the occurrence of IHR in zygotes via immunocytochemistry (ICC) for RAD51 in uninjected, RAD51-injected, Cas9-injected (with *Chd2*-targeting crRNA), and Cas9- and RAD51-injected zygotes at three stages of the cell cycle: G1/S, late S/G2, and M-phase. RAD51 staining is diffuse in the absence of DSBs, but strong RAD51 puncta that are indicative of nucleofilament formation appear in response to DNA damage, allowing direct visualization of RAD51-mediated repair events (Ladstätter and Tachibana-Konwalski, 2016). We did not see RAD51 puncta in uninjected embryos, but we observed a significant increase in RAD51 puncta solely during the G2 phase of the cell cycles in Cas9-injected embryos (Figure 4A,B). In agreement with our genotyping, co-injection of RAD51 with Cas9 resulted in the highest percentage of RAD51-positive embryos (Figure 4B). Additionally, we performed dual ICC/DNA-FISH with a RAD51 antibody and FISH probe specific to the *Chd2* genomic region to visualize the localization of RAD51 puncta in Cas9-injected embryos. Although this method was not robust enough to perform quantitative experiments, we exclusively visualized RAD51

nucleofilament formation at the *Chd2* genomic locus targeted by Cas9, suggesting a RAD51-dependent repair mechanism at Cas9-induced breaks in *Chd2*<sup>RH/+</sup> embryos (Figure S3A).

Though we did not observe RAD51 puncta in any uninjected embryos, we were surprised to see RAD51 foci in several embryos injected solely with RAD51 (Figure 4B). Embryos injected with RAD51 alone only exhibited single RAD51 puncta, but Cas-injected embryos were often observed with 2 or more puncta (Figure S3B,C), indicating the co-occurrence of RAD51-mediated repair events at the Cas9 cut site(s) and either off-target DSBs or sites of endogenous DNA damage. To determine whether RAD51 could be localizing to off-target DNA damage induced by Cas9, we performed targeted analysis of 24 loci with 4 mismatches to the *Chd2* crRNA. After pronuclear injection and whole-genome amplification of blastocyst DNA, we performed NGS-based amplicon sequencing of these loci in uninjected embryos, embryos only injected with Cas9, and embryos injected with Cas9 RNPs. Targeted NGS of the potential off-target found no evidence of off-target indel formation, demonstrating high specificity of the *Chd2* crRNA and indicating that the increased number of RAD51 puncta in some embryos was not due to off-target genomic modification by Cas9 (Figure S3D). This was further confirmed using genome-wide off-target analysis in two-cell injected embryos (GOTI; Zuo et al., 2019, 2020), which also failed to identify mutations at potential off-target sites (Figure S3E, Table S2). These findings and the observation that RAD51 nucleofilaments also form in RAD51-injected embryos, but not uninjected embryos, suggest that both Cas9-induced DSBs, endogenous DSBs, and DSBs caused by injection-related cellular stress are repaired by RAD51-mediated mechanisms. Taken as a whole, our imaging and sequencing studies demonstrate that RAD51 can be recruited to Cas9-induced DSBs during late S/G2 and that RAD51 nucleofilament formation can be stimulated by addition of exogenous RAD51.

### Enhancement of Interhomolog Repair Across Loci and Chromosomes

In support of our finding that IHR can occur in mouse zygotes during G2, a study that used light sheet microscopy to visualize the zygotic cell cycle in mice identified a short period of overlap between the maternal and paternal genomes during the late S/G2/M transition (Reichmann et al., 2018). However, only partial overlap is observed, suggesting that some chromosomal loci could be more permissible to IHR than others. Although we found that IHR is robust at both the *Chd2* and *Tyr* loci (Figures 2 and 3), both are located on mouse chromosome 7. This led us to question whether IHR occurs and can be enhanced on other chromosomes. First, we designed an IHR assay for the X chromosome. Using sperm from hemizygous *Mecp2* mutant mice (*c.882\_886>A*), we performed IVF with wild-type oocytes and targeted the wild-type maternal allele with Cas9. After culture and DNA purification, we used 80% of the genomic DNA as input for nested PCR to genotype the *Mecp2* locus and used the remaining 20% of genomic DNA for *Sry* PCR to determine sex. In female embryos injected only with Cas9, we observed a baseline IHR rate of 33% (16/49), but all 16 IHR-positive embryos were mosaic (Figure 5A). Co-injection of RAD51 increased the total IHR rate in females to 62% (24/39) and also increased the pure, non-mosaic IHR rate to 13% (5/39), demonstrating the ability of RAD51 to increase IHR rates on the X chromosome.



To design additional IHR assays for different autosomes we used the MGI SNP database to find SNP-dense loci between C57BL/6J and A/J mice, confirmed the SNP genotypes by sequencing, designed allele-specific sgRNAs, and performed *in vivo* screening to identify sgRNAs with high efficiency and allele specificity (data not shown). We settled on two loci for analysis: an intronic region of *Acs16* on chromosome 11 and an intronic region of *Kcnb2* on chromosome 1. We then performed IVF with sperm from A/J males and oocytes from C57BL/6J females, injected maternally-targeted Cas9 with or without RAD51, and genotyped blastocysts via Sanger sequencing. At the *Acs16* locus we observed a low overall IHR rate (12%; 9/74) in embryos injected with Cas9 alone, and a pure IHR rate of only 3% (2/74; Figure 5B). However, co-injection of RAD51 increased these rates to 32% (27/84) and 12% (10/84), respectively (Figure 5B). At the *Kcnb2* locus, the baseline IHR rate in Cas9-only embryos was 26% (18/68), but only 1 out of 68 embryos showed non-mosaic IHR (Figure 5C). Surprisingly, although RAD51 co-injection significantly increased the pure IHR rate to 13% (10/79), it had no effect on the overall IHR rate (27%, 21/79; Figure 5C), suggesting that the baseline IHR rate observed at this site is at its maximum. In total, our results at 4 sites on 3 autosomes and 1 site on the X chromosome demonstrate that endogenous IHR mechanisms are broadly active in the early embryo, but that the ability of RAD51 to enhance IHR is site-specific.

### Identification of Additional IHR Enhancers

Previous studies have not given significant insight into the molecular pathways governing interhomolog repair, but the low IHR rates in cells that efficiently perform HR suggests distinct mechanisms (Stark and Jasin, 2003a). Thus, we sought to identify additional IHR-associated proteins by performing a series of injections in *Chd2<sup>RH/+</sup>* zygotes with Cas9 and proteins associated with different DSB repair pathways: USP1/WDR48 (Fanconi anemia (FA) pathway regulator (Murai et al., 2011)), BCCIP (promotes BRCA2-mediated HR (Kelso et al., 2017; Lu et al., 2005; Wray et al., 2008)), participates in FA pathway (Moldovan and D'Andrea, 2009)), XRCC1 (promotes MMEJ and co-localizes with RAD51 (Dutta et al., 2017; Taylor et al., 2000)), and XRCC4 (promotes NHEJ and regulates V(D)J recombination (Critchlow et al., 1997; Normanno et al., 2017)). Supporting a role for canonical HR proteins in IHR, co-injection of USP1/WDR48 was capable of promoting IHR (Figure 6A) and BCCIP exhibited a striking effect on IHR, with 95% of edited embryos showing some degree of IHR (Figure 6A). Conversely, XRCC1 and XRCC4 were not capable stimulating IHR (Figure 6A). Together, these data indicate that IHR in the early embryo is driven by canonical HR pathways.

*RAD51* mutations have been found in Fanconi anemia and multiple cancers and a number of these mutations have been studied in depth. To gain additional mechanistic insights into IHR, we co-injected three different RAD51 mutants with Cas9 and *Chd2* crRNA into *Chd2<sup>RH/+</sup>* embryos: T131P (lacks FA pathway-associated function, but not canonical HR (Wang et al., 2015; Zadorozhny et al., 2017)), SA208–209ED (disrupted BRCA2-association (Yu et al., 2003)), and G151D (gain-of-function mutant (Marsden et al., 2016)). T131P injection did not increase IHR frequency (Figure 6B), indicating that FA pathway-related function of RAD51 function is critical for its role in interhomolog repair. Similarly, SA208–209ED did not increase IHR rates (Figure 6B), reinforcing the importance of

BRCA2-mediated RAD51 activation for IHR. With the G151D variant, we were surprised to find that in 27 zygotes injected we did not record a single indel event and observed some degree of interhomolog repair in all edited cells (Figure 6B). However, the apparent editing efficiency dropped to 22% (Figure 6C), suggesting that G151D either directly inhibits Cas9 nuclease activity or stimulates HR so robustly that the majority of DSBs are repaired through inter-sister HR. Co-incubation of Cas9 with G151D did not inhibit *in vitro* digestion of target (Figure 6D), supporting the hypothesis that G151D stimulates high levels of HR. We noted a similar decrease in apparent editing efficiency in BCCIP-injected embryos that was also not due to Cas9 inhibition (Figures 6D and S4), suggesting an inverse relationship between HR/IHR rates and indel rates in BCCIP- and G151D-injected embryos. Additional analyses of indel rates and indel-to-IHR ratios in embryos injected with RAD51, BCCIP, or RAD51 G151D revealed a drastic decrease in both measures compared to control embryos (Figure 6E and F). Furthermore, both BCCIP- and G151D-injected embryos showed significant decreases in these measures compared to embryos injected with wildtype RAD51. Together, our data argue that BCCIP and the RAD51 G151D mutant are highly efficient at stimulating both HR and IHR events at the expense of NHEJ.

### Properties of Interhomolog Repair Events

Observations in germ cells and somatic cells have found that the properties of meiotic IHR events are distinct from those of somatic HR, particularly in terms of the recombination tract length. Specifically, meiotic non-crossover IHR events tend to have recombination tracts of less than 100bp (Li et al., 2019), while recombination tracts in somatic cells often span hundreds to thousands of bases, depending on context (Donoho et al., 1998; Ertl et al., 2017; Liskay and Stachelek, 1986; Mansai et al., 2011; Neuwirth et al., 2007; Ruk et al., 2008; Smith et al., 2007). However, a study of IHR events in somatic cells found that ~90% had recombination tracts of less than 300bp, though some spanned as far as 6kb (Stark and Jasin, 2003b). We found that IHR in embryos is far more efficient than in somatic cells (LaRocque et al., 2011; Stark and Jasin, 2003b; Yusa et al., 2004) and may therefore be similar mechanistically to the process observed in germ cells, particularly considering their close temporal proximity.

To gain a better understanding of IHR properties in the early embryo, we made a strategy to analyze recombination tract lengths at the *Acs16* and *Kcnb2* loci. First, we performed IVF with A/J sperm and C57BL/6J oocytes and injected resulting zygotes with RAD51 and Cas9 RNPs targeting either locus. Next, we transferred 2-cell embryos to pseudopregnant females and allowed them to develop *in utero* for 10 days before harvesting the embryos and collecting genomic DNA. This protocol was designed to identify embryos that had undergone pure IHR and provide sufficient amounts of gDNA for tiled SNP genotyping upstream and downstream of the cut sites, as well as long-range PCR and TOPO cloning for analysis SNP genotypes on individual alleles (Figure 7A). We identified 7 *Acs16* and 5 *Kcnb2* embryos that had undergone pure IHR (Figure 7B) and performed targeted PCR and sequencing of SNPs located between 3kb and 20kb upstream and downstream of the Cas9 target sites. This revealed heterozygosity in all Cas9-injected embryos and controls (Figure 7B), ruling out widespread loss of heterozygosity. Our analysis strategy for cloned alleles was limited by the presence of repeat elements and/or the presence of SNPs, but we were

able to screen a 2.6kb region (2kb upstream + 600bp downstream of cut site) region at the *Acs16* locus and a 3.1kb region (1.5kb upstream and downstream of cut site) at the *Kcnc2* locus. In all embryos, PCR amplification of the target region failed to identify large deletions indicated by the presence of multiple PCR products (Figure S5). After TOPO cloning, we screened at least 16 clones from each embryo by Sanger sequencing all SNP-containing loci. At the *Acs16* locus, 5/7 embryos were homozygous for the A/J allele at all SNPs in 100% of clones, suggesting recombination tract lengths >2kb upstream of the cut site and >304bp downstream of the cut site (Figure 7C). In 2/7 embryos, we identified alleles carrying the A/J SNPs at the cut site, but C57BL/6J SNPs 2kb upstream (Figure 7C). In one of these embryos, the switch back to the C57BL/6J genotype occurred between the cut site and the SNP 178bp upstream (Figures 7C and S5–6). In both of these embryos, the alleles with quantifiable recombination tract lengths represented a small fraction of the total alleles (2/22 in embryo #5 and 3/19 in embryo #7), indicating that these embryos may be mosaic for multiple IHR events. We observed a similar pattern at the *Kcnc2* locus, with 3/5 embryos completely converted to A/J across the 3kb window and 2/5 carrying alleles converted to A/J at the cut site, but carrying C57BL/6J SNPs at sites ~1.5kb upstream and/or downstream (Figure 7C). Of these two embryos, one had an upstream conversion tract >1.5kb and a downstream conversion tract <1.5kb, while the second had an upstream conversion tract <1.5kb and a downstream conversion tract <213bp (Figures 6C and S5–6). At this site we observed evidence of mosaicism, with >2 alleles present in embryos #1 and #4, but we also observed >2 alleles in control embryos as a result of template switching during the initial PCR reaction. Importantly, this template switching does not alter our conclusions, as it can only be observed at sites that are heterozygous for a given SNP in the input pool of DNA. Thus, our results show that the conversion tracts for IHR in the early embryo are generally 1.5–3kb in both directions, but that the properties of individual IHR events can vary, with some conversion tracts as short as several hundred base pairs from the DSB. Together, these findings indicate that zygotic IHR utilizes canonical HR pathways and has features similar to that of somatic HR.

## Discussion

Previously, Ma *et al.* reported efficient interhomolog repair in human zygotes, leading others to question how such a process is possible given the physical separation of homologous chromosomes into separate pronuclei (Egli et al., 2018). This near complete separation of the maternal and paternal genomes was elegantly described in a study from Reichmann *et al.* that used time-lapse light sheet microscopy to follow mitosis in mouse zygotes. However, their data clearly show that there is a window of approximately 45 minutes following nuclear envelope breakdown when there is consistent overlap between the maternal and paternal genomes (Reichmann et al., 2018). Furthermore, this overlap occurs in the absence of a targeted DSB and recent studies have found that DNA damage induces reorganization of the genome and relocation of the broken chromosome prior to repair (Caridi et al., 2018; Oshidari et al., 2018). Our ICC experiments found that RAD51 localizes to Cas9 cut sites at or slightly before the time of nuclear envelope breakdown (Figure 4), suggesting that IHR occurs during this window. However, Sanger sequencing, amplicon sequencing, and sequencing of TOPO-cloned alleles all uncovered evidence of mosaicism at rates consistent

with IHR during the 2- and 4-cell stages (Figures S2, S5, Table S2), meaning that IHR is a common method of DSB repair in the early embryo. This is further supported by our observation that although embryos injected with both Cas9 and RAD51 display a higher frequency of RAD51 puncta than embryos injected with Cas9 alone, the difference is not nearly as significant as the difference observed by genotyping, which captures IHR events occurring any time before embryo collection. Altogether, our data suggest that the early embryo is uniquely permissive to IHR because of high baseline HR rates and frequent availability of the homolog as a template for repair.

Understanding whether there is a unique mechanism for IHR is critical for future efforts to induce and/or enhance IHR. We found that RAD51, the BRCA2-interacting protein BCCIP, and the Fanconi anemia pathway-associated protein complex of USP1/WDR48 are all capable of increasing the frequency of interhomolog repair in the early embryo (Figures 3, 5). RAD51 and BCCIP participate in multiple homologous recombination pathways (D'Andrea and Grompe, 2003; Lu et al., 2005; Miele et al., 2015) and although USP1/WDR48 is most well-known for its regulation of the Fanconi anemia pathway through deubiquitylation of FANCD2/I, it can also promote HR through FA-independent pathways (Cukras et al., 2016; Liang et al., 2016; Lu et al., 2005; van Twest et al., 2017; Yang et al., 2011). Based on this knowledge, IHR enhancement by RAD51, BCCIP, and USP1/WDR48 does not clearly implicate a specific pathway in the process. However, the observation that the RAD51 T131P mutant, which is specifically defective in the FA pathway-associated function of RAD51 (Wang et al., 2015; Zadorozhny et al., 2017) suggests that IHR in the early embryo could be mediated by an FA-associated pathway.

Though applications of IHR in the early embryo are limited in mice, this study provides the basis for future work to enhance IHR in somatic cells for therapeutic purposes. While recent years have seen a rapid expansion of clinical gene editing efforts, HDR-based strategies still suffer from low efficiency and carry the risk of unwanted integration of donor DNA throughout the genome. IHR has the potential to overcome these problems because it relies upon endogenous pathways and the patient's own wild-type allele for correction of the deleterious mutation. We show that IHR can copy deletions, point mutations, and combinations of both between alleles, demonstrating its potential use for correcting a wide variety of genetic lesions. Additionally, we find that BCCIP and the RAD51 G151D mutant are factors that can both enhance IHR and reduce indel rates, which are of concern for many clinical gene therapy approaches. One concern regarding IHR and its clinical use is the induction of widespread loss of heterozygosity or genomic rearrangements. However, we identified single alleles in embryo #1 of the *Kcnb2* group where the genotype was converted to A/J at the Cas9 cut site but remained C57BL/6J on both sides (Figures 7 and S5–6), indicating that IHR occurs through gene conversion without crossover. Importantly, we found that IHR recombination tract lengths are generally several hundred to several thousand base pairs long, but less than 5kb, suggesting that widespread loss of heterozygosity is not a major risk. Of note, however, recent studies have found that intrachromosomal recombination can occur between sites with highly homologous sequences, meaning that genome-wide homology must be considered before designing IHR-based strategies for gene conversion (Javidi-Parsijani et al., 2020; Liang et al., 2015). If methods to induce IHR in somatic cells can be developed, the recombination tract lengths associated with IHR enable

the use of guides targeted to intronic regions adjacent to disease-causing mutations, decreasing the risk of unintended indels and offering more potential sites for the allele-specific targeting required to induce IHR. Looking forward, studies designed to probe the endogenous mechanisms of IHR, identify factors limiting its occurrence in somatic cells, and develop methods to safely and efficiently induce IHR in diverse cell types are necessary, but IHR represents a promising approach for applications in molecular biology, biotechnology, and gene therapy.

### Limitations of the Study

Although we have definitive evidence that interhomolog repair occurs in mouse embryos and can be enhanced by multiple proteins, we cannot rule out that a small fraction of the IHR-positive embryos are false-positives resulting from large deletions. Additionally, we cannot differentiate between error-free NHEJ and RAD51-stimulated inter-sister HR and thus cannot definitively conclude that decreases in observed editing efficiency are due to solely to increased rates of inter-sister HR. Last, without additional experiments in both species, findings from our study cannot be directly compared to those in human embryos.

## STAR Methods

### RESOURCE AVAILABILITY

**Lead Contact**—Further information and requests for resources and reagents should be directed to the Lead Contact, Guoping Feng (fengg@mit.edu).

**Materials Availability**—*Chd2*<sup>R1684H</sup> mice will be available from The Jackson Laboratory after initial characterization has been completed for a separate study.

**Data and Code Availability**—The amplicon sequencing included in this study has been submitted to the Sequence Read Archive and can be found under accession number PRJNA614534. Additional raw data for the figures in this manuscript can be obtained from the Lead Contact or corresponding authors upon request.

### EXPERIMENTAL MODEL AND SUBJECT DETAILS

All mouse work was performed with the supervision of the Massachusetts Institute for Technology Division of Comparative Medicine (DCM) under protocol 0416–024–19, which was approved by the Committee for Animal Care (CAC). All procedures were in accordance with the guidelines set forth by the Guide for Care and Use of Laboratory Animals, National Research Council, 1996 (institutional animal assurance no. A-3125–01). For all experiments except those targeting the *Mecp2* locus, we did not perform sex genotyping and therefore used males and females. At the *Mecp2* locus we genotyped all embryos, but only analyzed female embryos. Embryonic experiments analyzed morula and blastocyst-stage embryos. Analysis of IHR conversion tract length was performed using E10.5 embryos. Genotyping of F<sub>0</sub> and F<sub>1</sub> animals was performed using tissue from animals collected at ~P10.

## METHOD DETAILS

**Preparation of Injection Mixtures:** tracrRNA, crRNAs, and ssODNs were synthesized by Integrated DNA Technologies and modified sgRNAs were synthesized by Synthego (see Table S3 for sequences). All injection mixtures were prepared in a final volume of 50 $\mu$ L according to the following protocol. Using RNase-free water, reagents, and consumables, crRNA (final concentration 0.61 $\mu$ M), tracrRNA (final concentration 0.61 $\mu$ M), and ultrapure Tris-HCl, pH 7.39 (final concentration 10mM, ThermoFisher) were mixed and incubated at 95°C for 5 minutes. The mixtures were cooled to room temperature for 10 minutes on the benchtop and then EnGen Cas9 NLS, *S. pyogenes* (New England Biolabs) was added to a final concentration of 30ng/ $\mu$ L. The mixtures were incubated at 37°C for 15 minutes before adding any remaining components: ssODN (final concentration 30ng/ $\mu$ L), RAD51 (Creative Biomart, 134H, final concentration 10ng/ $\mu$ L), or additional recombinant proteins (described below, 10ng/ $\mu$ L). Injection mixtures were stored on ice and briefly heated to 37°C prior to injection. Injection mixtures utilizing sgRNAs were prepared at the same final concentration in the same buffer, but the 95°C incubation step was omitted. For experiments utilizing RS-1, embryos were cultured in KSOM-AA (EMD Millipore MR-121-D) with 7.5 $\mu$ M RS-1 (Sigma) dissolved in DMSO or DMSO (Sigma, 1:1000) for 24 hours, washed, and cultured in EmbryoMax FHM HEPES Buffered Medium (Sigma) until collection for genotyping.

**Recombinant Proteins:** For experiments using wild-type recombinant proteins, the following proteins were used: RAD51 (Creative Biomart RAD51–134H), USP1/WDR48 (Creative Biomart USP1&WDR48–1067H), BCCIP (Origene TP303061), XRCC1 (TP304952), XRCC4 (Origene TP312684). For experiments using mutant RAD51, custom RAD51 preparations were produced by Creative Biomart according to their standard protocol for producing the wildtype RAD51 used in all other experiments. DNA sequences used for cloning the mutant forms of *Rad51* are described in Table S3. All RAD51 mutants were modeled based on human *RAD51* transcript variant 4 (NCBI accession NM\_001164269), as this is the transcript variant of the wildtype RAD51–134H protein used in all other experiments. Identity and/or purity of all recombinant proteins used in this study are shown in Figure S7A–C (methods described below). Biochemical activity of recombinant RAD51 used in this study is shown in Figure S7D,E (methods described below).

**Total Protein Staining and Western Blotting:** 1 $\mu$ g of each recombinant protein was mixed with 2X Laemmli Sample Buffer (Bio-Rad) and heated to 95°C for 5 minutes. After brief centrifugation, samples were loaded into 4–15% Mini-PROTEAN TGX Pre-Cast gels (Bio-Rad) along with 5 $\mu$ L PrecisionPlus Protein Kaleidoscope Prestained Protein Standards (Bio-Rad) and run at 200V for 40 minutes in 1X Tris/Glycine/SDS running buffer. Protein was transferred to nitrocellulose at 100V for 1 hour at 4°C and total protein was visualized using REVERT Total Protein Stain (LI-COR Biosciences) according to the manufacturer's protocol. For RAD51 Western blotting in Figure S7A, REVERT Total Protein Stain was reversed according to the manufacturer's protocol, the membrane was blocked at room temperature for 1 hour in TBST containing 5% non-fat dry milk. Primary antibody (Rb anti-RAD51, Abcam ab63801, 1:500) was diluted in blocking buffer and applied to the membrane overnight at 4°C. Following washes with TBST, secondary antibody (IRDye



800CW Gt anti-rabbit IgG H+L, LI-COR 925–32211, 1:15,000) was diluted in blocking buffer and applied to the membrane for 1 hour at room temperature in the dark. The membrane was then washed and imaged. For all experiments, imaging was performed on an Odyssey CLx Imaging System with ImageStudio (LI-COR Biosciences). Coomassie staining and Western blots in Figure S7B were performed by Creative Biomart.

**ssDNA Binding Assay:** To test the activity of the RAD51 variants utilized in this study, binding to ssDNA was assayed based upon a previously described protocol (Chen et al., 2015). 1 $\mu$ g recombinant RAD51 protein was mixed with 20 $\mu$ M  $\phi$ X174 ssDNA (NEB, N3023) in fresh 1X reaction buffer containing 25mM HEPES (pH7.5), 1mM MgCl<sub>2</sub>, 30mM NaCl, 1mM DTT, 0.4mM 2-mercaptoethanol, 0.03mM EDTA, 0.1mg/mL BSA, 2% glycerol, and 1mM ATP. The mixtures were incubated for 30 minutes at 37°C to form complexes. Following incubation, mixtures were loaded onto 0.8% TAE agarose gel and run at 25V for 16 hours. Gels were stained with 1X GelStar Nucleic Acid Gel Stain (Lonza, Cat. No. 50535) in TAE for 2 hours in the dark and then trans-illuminated with UV light for imaging. Wild-type RAD51 and all assayed mutants of RAD51 functioned as expected based on previously published data (Chen et al., 2015; Marsden et al., 2016; Wang et al., 2015; Yu et al., 2003).

**Near-Infrared Strand Exchange Assay:** Recombinant RAD51 strand exchange activity was assessed using a modified version of a previously described strand exchange assay (Wang et al., 2015). The assay used three oligos, described in Table S3: an unlabeled 40-mer oligo, a complementary 40-mer oligo labeled on its 5' end with IRDYE-800, and a 167-mer oligo containing the sequence of the unlabeled 40-mer (complementary to the labeled 40-mer). A 1:1 solution of the 40-mer oligos (40nM final concentration for each) was heated to 95°C for 5 minutes in a thermal cycler and allowed to cool 4°C at a ramp speed of 0.1°C/second. The strand exchange reaction mixture was assembled on ice, containing the unlabeled 167-mer (final concentration 4nM), RAD51 (final concentration 440nM), and final concentration 1X reaction buffer (25mM TrisOAc pH7.5, 1mM MgCl<sub>2</sub>, 2mM CaCl<sub>2</sub>, 0.1mg/mL BSA, 2mM ATP, and 1mM DTT). The reaction was incubated at 37°C for 10 minutes to allow RAD51 nucleofilament formation and then the annealed 40-mer oligos were added to a final concentration of 4nM. The reaction was incubated at 37°C for 30 minutes and then terminated via the addition of SDS (final concentration 0.25%) and proteinase K (final concentration 0.5 $\mu$ g/ $\mu$ L) and further incubation at 37°C for 10 minutes. Samples were then separated on a 5% TBE gel run in 1X TBE at 60V for 70 minutes and imaged on a LI-COR Odyssey CLx imaging system.

**Natural Mating for Zygotic Injections:** Female mice (4–5 weeks old, C57BL/6NTac) were superovulated by IP injection of PMS (5 IU/mouse, three days prior to microinjection) and hCG (5 IU/mouse, 47 hours after PMS injection) and then paired with males. Pregnant females were sacrificed by cervical dislocation at day 0.5pcd and zygotes were collected into 0.1% hyaluronidase/FHM (Sigma). Zygotes were washed in drops of FHM and cumulus cells were removed. Zygotes were cultured in KSOM-AA for one hour and then used for microinjection.

**In Vitro Fertilization for Zygotic Injections:** *In vitro* fertilization was performed using FERTIUP Mouse Preincubation Medium and CARD MEDIA (Kyudo Company) according to the manufacturer's protocol. Non-virgin *Chd2<sup>RH/RH</sup>*, *Mecp2<sup>del/Y</sup>*, and A/J (The Jackson Laboratory, Stock No. 000646) males that were >8 weeks old were used as sperm donors. For experiments using *Chd2* or *Mecp2* sperm, oocytes from C57Bl/6NTac females (Taconic) were used. For experiments using A/J sperm, oocytes from C57Bl/6J females (The Jackson Laboratory, Stock No. 000664) were used. Following IVE, embryos were cultured for ~8 hours and then injected using the PNI protocol described below.

**Zygotic Microinjections:** Except for Figure 1, all experiments described in this manuscript show data from a minimum of two days of injections. For all experiments except the CPI experiments described in Figure 1, the male pronucleus was injected. Injections performed for the CPI portion of Figure 1 were targeted to the cytoplasm. All microinjections were performed using a Narishige Micromanipulator, Nikon Eclipse TE2000-S microscope, and Eppendorf 5242 microinjector. Individual zygotes were injected with 1–2pL of injection mixture using an “automatic” injection mode set according to needle size and adjusted for clear increase in pronuclear volume. Following injections, cells were cultured in KSOM-AA until collection for genotyping. For experiments giving rise to F<sub>0</sub> animals, embryos were surgically implanted into pseudopregnant CD-1 females (Charles River Laboratories, Strain Code 022) 24-hours post-injection and allowed to develop normally until natural birth.

**Conditions for Embryo Collection, DNA Purification, and Genotyping:** To avoid contamination and ensure accuracy and consistency of genotyping results, embryo collection, DNA purification, and genotyping were all performed using special protocols and conditions. For both embryo collection and PCR, all plates, tubes, filter tips, strip caps, plate holders, ice buckets, and aliquots of nuclease-free water (not DEPC-treated) were UV-sterilized for >15 minutes in a laminar flow hood. All embryo manipulation and PCR was performed in a laminar flow hood. For PCR, all reagents (buffer, MgCl<sub>2</sub>, dNTPs, primers, polymerase) were aliquoted in the laminar flow hood upon receipt from the manufacturer and were solely used for embryo genotyping. No template controls were included with all PCR runs to rule out the presence of background DNA that could influence genotyping results.

**Embryo Collection and DNA Purification:** Embryos were collected between the morula and blastocyst stage (3–4 days post injection) into 4μL nuclease-free water. After collection, 4μL of 2X embryo digestion buffer was added to each sample (final concentrations: 125μg/mL proteinase K, 100mM Tris-HCl pH 8.0, 100mM KCl, 0.02% gelatin, 0.45% Tween-20, 60μg/mL yeast tRNA) and embryos were lysed for 1 hour at 56°C. Proteinase K was inactivated via incubation at 95°C for 10 minutes and DNA was stored at –20°C until use.

**Mouse Tail DNA Purification:** Tail tissue (~0.5cm length) was collected from individual animals, placed in 75μL alkaline lysis buffer (25mM NaOH, 0.2mM EDTA), and incubated

at 95°C for 30 minutes. Digestion was stopped via addition of 75µL neutralization buffer (40mM Tris-HCl pH 5.0). Samples were stored at 4°C until genotyping.

**Chd2<sup>RH</sup> PCR:** *Chd2<sup>RH</sup>* genotyping was performed via a two-step, nested approach. Except for experiments described in Figure 3, all 8µL of embryo DNA were used as input for the initial, long round of PCR. Genotyping of mouse pups and adult animals was performed using 2µL purified tail DNA. For all embryo genotyping, reaction mixtures were set up in a UV-sterilized laminar flow hood using sterile reagents and filter tips to avoid contamination. All PCR was performed using Biolase DNA Polymerase (Bioline), fresh aliquots of dNTPs (New England Biolabs), and 2% DMSO (final concentration). The first PCR reaction of the nested PCR was performed using the C2RH-Long\_F/R primer pairs listed in Table S3. Primer pairs C2RH-Long\_F1/R1 and C2RH-short\_F1/R1 were used for Figures 1–3, as well as Supplementary Figures 1 and 2. All other experiments utilized primer pairs C2RH-Long\_F2/R2 and C2RH-short\_F2/R2, which was designed to amplify a larger genomic region as a way to further rule out large deletions that could disrupt PCR primer binding sites. 20 cycles of amplification were performed using 30 second extension and annealing times and an annealing temperature of 67°C. Nested PCR was then performed using 2µL of the initial 25µL PCR reaction as input. The C2RH-Short\_F/R primer pairs listed in Table S3 were used for this PCR, with sets 1 and 2 being used as described above. Thirty-five cycles of amplification were performed using 30 second extension and annealing times and an annealing temperature of 68°C.

**Tyr<sup>C89S</sup> PCR:** Initial PCR was performed using 2µL purified tail DNA. The longer amplification of the nested PCR reaction was performed using the Tyr-Long\_F/R primer pair listed in Table S3. PCR was performed using Biolase DNA polymerase (Bioline) and a final concentration of 2% DMSO. Twenty cycles of PCR were run with 30 second annealing and extension steps and an annealing temperature of 66°C. Nested PCR was performed using 2µL of the initial 25µL PCR reaction and the Tyr-Short\_F/R primer pair listed in Table S3. The same PCR conditions were used for the nested PCR as were used for the initial PCR.

**Sanger Sequencing:** For all sequencing reactions, 5µL of PCR product was mixed with 3µL dH<sub>2</sub>O and 2µL ExoSAP (Exonuclease I, NEB #M0293 and rSAP, NEB #M0371). Products were incubated at 37°C for 30 minutes to degrade primers and dephosphorylate dNTPs and enzymes were then heat inactivated at 80°C for 15 minutes. 5µL 5µM sequencing primer was then added to each mixture and samples were submitted to Genewiz for Sanger sequencing. Sequence files (.ab1) were blinded using a freely-available Perl script (<https://github.com/jimsalterjrs/blindanalysis>) and analyzed using SnapGene. To identify IHR events in mosaic samples, we compared the major and minor peak heights at the relevant SNPs using 4Peaks (Nucleobytes), analyzed traces with ICE (Synthego), or a combination of both. Sequences showing 3:2 ratio of major allele to minor allele at both sites were called IHR-positive.

**On-Target Next-Generation Amplicon Sequencing:** Blastocyst DNA from uninjected embryos and embryos injected with Cas9, *Chd2* crRNA, and tracrRNA was collected as described above. Half of the DNA was used for the previously described Sanger

sequencing and analysis protocol. After analysis, 10 uninjected, 10 “pure IHR,” and 32 embryos with varying levels of *Chd2<sup>RH</sup>* allele were selected for subsequent next-generation sequencing. For these embryos, the second half of the genomic DNA was used as input for nested PCR (primers described in Table S3) using Biolase DNA Polymerase (Bioline). To ensure capture of all PCR products, PCR products were purified using the DNA Clean & Concentrator Kit (Zymo Research, D4033) according to the manufacturer’s instructions. Purified PCR products were then submitted for sequencing with Genewiz’s Amplicon-EZ service. Fastq files were then batch analyzed using the CRISPResso2 command line tool (Clement et al. 2019) in HDR mode using default settings and the *Chd2<sup>RH</sup>* allele sequence as the HDR template. Since the *Chd2<sup>RH</sup>* allele contains two point mutations in close proximity to the Cas9 cut site, certain indels can obscure those sites, making the program unable to definitively call an outcome and classifying those reads as ambiguous. Total indels were therefore characterized as the sum of NHEJ and ambiguous reads. PCR-induced mutations or errors during IHR can create “imperfect” knock-in alleles and thus, total *Chd2<sup>RH</sup>* allele frequency was calculated as the sum percentage of *Chd2<sup>RH</sup>* and imperfect *Chd2<sup>RH</sup>* reads. Sanger sequencing traces and estimated allele frequencies, as well as read counts and NGS-derived allele frequencies can be found in Table S2. All sequencing data was deposited in the NCBI Sequence Read Archive (SRA) under project accession PRJNA614534.

**In vitro Cas9 Digestion Assays:** Wild-type or *Chd2<sup>RH/RH</sup>* genomic DNA was used as input for PCR using the conditions described above and the primers specified in Table S3. After confirmation of a single band via gel electrophoresis, the PCR reactions were purified using the DNA Clean & Concentrator kit (Zymo) according to the manufacturer’s instructions. crRNA and tracrRNA were diluted 1 $\mu$ M in Nuclease-free Duplex Buffer (IDT) and incubated at 95°C for 5 minutes before being allowed to cool to room temperature on the bench. Digestion mixtures were made in separate tubes by combining nuclease-free water, 10X Cas9 Nuclease Reaction Buffer (final concentration 1X, New England Biolabs), 1 $\mu$ L of the cooled crRNA/tracrRNA duplex, and, if necessary, 1 $\mu$ L of EnGen Cas9 NLS, *S. pyogenes* (New England Biolabs). These mixtures were heated to 37°C for 10 minutes before adding 250ng PCR product and, if necessary, RAD51 G151D (10ng/ $\mu$ L final concentration, custom-produced by Creative Biomart) or BCCIP (10ng/ $\mu$ L final concentration, Origene TP303061). Digestion was performed at 37°C for 1 hour, Cas9 was denatured at 95°C, 6X Purple Gel Loading Dye (New England Biolabs) was added to a final concentration of 1X, and the samples were allowed to passively cool to room temperature. After cooling, reactions were separated by electrophoresis in 2% agarose gel, post-stained with GelRed Nucleic Acid Gel Stain (Biotium) according to manufacturer’s instructions and visualized using an InGenius Gel Documentation System (Syngene).

**Genomic Copy-Number qPCR:** To determine copy number at specific genomic loci, we developed a strategy utilizing multiplex nested qPCR. We first performed multiplex amplification of both the edited *Chd2* region (Chr7) and a region of the *Gapdh* promoter (Chr6) that we have previously targeted for ChIP experiments (Wilde et al., 2017) in a short round of PCR (10 cycles). We then used this PCR product as input for two separate nested qPCR reactions, one targeting the *Gapdh* control locus (2N) and one targeting the *Chd2*

locus (unknown copy number). *Chd2* signal was then normalized to the *Gapdh* signal to determine copy number at the *Chd2* locus. As a 2N control, we used DNA from uninjected embryos. As a 1N control we generated a mouse line harboring a large deletion at the *Chd2* locus (see below) and used heterozygous embryos for qPCR. To test for large deletions in Cas9-injected embryos presumably having undergone IHR, we isolated genomic DNA from Cas9/*Chd2* crRNA/tracrRNA-injected blastocysts, used 50% for genotyping as described above, and then randomly-selected 10 “pure IHR” blastocysts for genomic qPCR. Initial nested PCR was performed using Biolase DNA Polymerase (Bioline). qPCR was performed using SsoAdvanced Universal SYBR Green Supermix (Bio-Rad). Primers are listed in Table S3.

**Generation of the *Chd2*<sup>del</sup> Mouse Line:** Zygotes were prepared for injection via natural mating and pronuclear injections were performed as described above. Embryos were cultured overnight in KSOM-AA and embryos that failed to undergo cleavage were discarded. Two-cell embryos were surgically implanted into pseudopregnant CD-1 females (Charles River Laboratories, Strain Code 022) and allowed to develop until natural birth. Pups were genotyped at postnatal day 21 using the primers described in Table S3.

**Immunocytochemistry:** First, embryos were blinded before staining and analysis. Zygotes were collected during G1 (~9hpf, ~1hpi, PN2), G2 (~14.5hpf, ~6.5hpi, PN5), or M-phase (~16hpf, ~8hpi) and fixed overnight at 4°C in 4% PFA + 0.1% Tween-20 in PBS and then briefly transferred to acidified Tyrode’s (Sigma T1788) to remove the zona. Collection times and cell cycle stages were determined empirically based on morphology (Santos et al., 2013). Specifically, G2 embryos were fixed when maternal and paternal pronuclei had overlapped and nuclear envelopes were undergoing clear breakdown (at least one no longer visible). M-phase embryos were selected ~1 hour after complete breakdown of the nuclear envelopes. After washing in PBS + 0.1% Tween-20 (PBST), zygotes were permeabilized in PBS + 1% Triton X-100 for 1 hour at 4°C and then blocked for 1 hour at room temperature in blocking solution (PBS + 3% BSA + 5% normal goat serum). Primary antibody (rabbit anti-RAD51, Abcam ab63801, 1:500) was diluted in blocking solution and applied to coverslips overnight at 4°C. Cells were washed 3 times in PBST before application of secondary antibody (goat anti-rabbit IgG conjugate, Alexa Fluor 488, ThermoFisher A-11008) diluted in blocking solution for 1 hour at room temperature. Nuclei were counterstained with DAPI and coverslips were mounted to slides with Fluoromount Aqueous Mounting Medium (Sigma F4680). Cells were imaged on an Olympus Fluoview FV1000 confocal microscope with a 60X oil immersion objective and variable digital zoom. For all cells, we acquired z-stacks incorporating both pronuclei. Raw image files were exported to FIJI (Schindelin et al., 2012) for Z-projection (sum slices), channel splitting, and scale bar generation.

**Off-Target Next-Generation Amplicon Sequencing:** Off-target analysis by NGS was performed as previously described (Li et al., 2020). Briefly, pre-genotyped blastocyst stage embryos were subjected to whole genome amplification using REPLI-g Single Cell kit (Qiagen) according to manufacturer’s instructions. Equal amounts of amplified DNA were mixed and 3 pools were prepared: an uninjected pool from 8 embryos, a Cas9-only pool



from 12 embryos injected with Cas9 protein but no crRNA/tracrRNA, and a pool from 19 embryos injected with Cas9 protein, *Chd2* crRNA, and tracrRNA. Twenty-six off-target candidate sites for cr*Chd2* containing up to 4 mismatches were predicted and primer pairs were designed using CRISPOR (Concordet and Haeussler, 2018). All sites were PCR amplified from each pool using Herculase II Fusion DNA Polymerases (Agilent) and gel purified using ZymoClean Gel DNA Recovery kit (Zymo Research). Equimolar amounts of the twenty-six PCR amplicons of each pool were mixed and subjected to library construction for Illumina sequencing with reagents from TruSeq Stranded mRNA Sample Preparation kit (Illumina) according to the manufacturer's instructions. Barcoded libraries were mixed and sequenced on a MiSeq (Illumina) with 150bp paired-end reads and a 6-base Index 1 read to an averaged depth of 200,000 reads per locus per pool. Sequencing was analyzed in three batches using CRISPResso2 (Clement et al. 2019). For each batch, we ran CRISPResso's CRISPRessoPooled tool. Since the amplicon sites that we considered for analysis were relatively short (minimum of 66 bp, maximum 145 bp, median 126 bp), CRISPResso failed to analyze some amplicons due to the low number of reads that aligned properly on the amplicon. Furthermore, the poor mapping to the amplicons caused some artifactual deletions in the reads. Therefore, we extended all amplicon sequences to 250 bases. We also trimmed the reads 5 bases from the start and 55 bases from the end, and decreased the minimum alignment score from the default of 60 to 10, in order to allow more mapping of reads (allowing more reads in the analysis negatively biases our results). Even with these modifications, 5 amplicons still failed the CRISPResso analysis. We discarded two amplicon regions since they are on L1 repeat regions (OT21 and OT22), and we performed another round of deep sequencing on 3 amplicons (OT15, OT18, and OT20), this time using a longer region (303, 311 and 332bp). These amplicons were sequenced using the Amplicon-EZ service from Genewiz and we re-analyzed them using the web-based CRISPResso2 tool (<http://crispresso.pinelloab.partners.org>). All sequencing data was deposited in the NCBI Sequence Read Archive (SRA) under project accession PRJNA614534.

**Genome-wide Off-Target Analysis by Two-Cell Embryo Injection (GOTI):** GOTI was performed as previously described (Zuo et al., 2019, 2020). Briefly, IVF was performed as described above using homozygous Ai14 (The Jackson Laboratory, Stock No. 007908) males and C57Bl/6NTac females. A mixture of Cas9 protein (final concentration 30 ng/μl) and Cre mRNA (final concentration 2 ng/μl), Cas9 protein (final concentration 30 ng/μl), *Chd2* crRNA (final concentration 0.61 μM), tracrRNA (final concentration 0.61 μM) and Cre mRNA (final concentration 2 ng/μl), or Cas9 protein (final concentration 30 ng/μl), *Chd2* crRNA (final concentration 0.61 μM), tracrRNA (final concentration 0.61 μM), RAD51 (Abcam ab63808, final concentration 10 ng/μL) and Cre mRNA (final concentration 2 ng/μl) was injected into both the nucleus and cytoplasm of one blastomere of 2-cell stage embryos. The injected embryos were transferred into pseudopregnant CD-1 females as described above.

Mosaic fetuses were harvested at E14.5, minced, and enzymatically dissociated in 0.05% 5 mL Trypsin-EDTA at 37°C for 30 minutes. Digestion was then stopped by the addition of 5mL DMEM/10% FBS. Digested tissues were further homogenized by pipetting 30–40 times using 1ml pipette tips and were then spun down and pellets were resuspended in



DMEM/10% FBS and filtered through a 40 $\mu$ m cell strainer. The tdTomato-positive/tdTomato-negative cells were then sorted by FACS. The purity of sorted cells was confirmed to be >95% by fluorescence microscopy and PCR cloning analyses.

Genomic DNA was extracted from sorted cells using the NucleoSpin Tissue kit (Macherey-Nagel). The libraries for whole genome sequencing (WGS) were prepared using the Illumina DNA PCR-Free Prep kit (Illumina) with barcodes, pooled, and run on a NovaSeq 6000 (Illumina) to generate mean coverages from 30X to 83X.

The off-target indels and SNVs were identified by comparing the tdTomato-positive cells with tdTomato-negative cells from the same embryo using three variant calling algorithms, as detailed in the GOTI method (Zuo et al., 2019, 2020). In detail, BWA (v0.7.12) was used to map quality-filtered sequencing reads to the reference genome (mm10). Picard tools (v2.3.0) was then applied to sort and mark duplicates of the mapped BAM files. To identify the genome-wide *de novo* single nucleotide variants with high confidence, we separately ran three algorithms that detect single nucleotide variants present in the tdTomato-positive cells but not present in tdTomato-negative cells: Mutect2 v3.5 (Benjamin et al., 2019), Lofreq v2.1.2 (Wilm et al., 2012) and Strelka v2.7.1 (Kim et al., 2018). Only SNVs called by all three SNV-detection algorithms were considered to be true variants. To detect indels present in tdTomato-positive cells but not in tdTomato-negative cells, we used Mutect2 v3.5, Strelka v2.7.1, and Scalpel v0.5.3 (Fang et al., 2016). Once again, only indels called by all three algorithms were considered to be true *de novo* indels. As previously done (Zuo et al., 2019, 2020), we annotated the SNVs and indels using ANNOVAR v2020-06-08 (Wang et al., 2010) and performed additional filtering on the variants by choosing variants with allele frequencies at least 10%. The off-target SNVs and indels were compared to the *Chd2* guide RNA sequence by blasting the genomic sequence of the SNV/indel 17 bases upstream and 5 bases downstream with the 23-base *Chd2* guide RNA sequence. We also obtained the sequence in the reverse strand, 5 bases upstream and 17 bases downstream of the SNV/indel and compared using blast with the *Chd2* guide RNA sequence. To further analyze the off-target SNVs and indels, we overlapped them with predicted off target sites using two algorithms: Cas-OFFinder v2.4 (Bae et al., 2014) and CRISPOR v4.98 (Concordet and Haeussler, 2018). For CRISPOR, we utilized the web-based tool with default settings. We ran Cas-OFFinder twice, first with parameter 4 mismatches (MM) and second with parameter 9 MM. We then looked for overlap between the genomic regions 18 bases upstream and 18 bases downstream of each SNV/indel and the off-target sites predicted by CRISPOR and Cas-OFFinder. We did not observe any indels overlapping with putative off-target sites, but for SNVs overlapping with potential off-target sites we ruled them out as true off-targets based on the following observations: 1) one overlapping SNV was found in the Cas9-only condition (8 mismatches), 2) all SNVs found in the Cas9 + crRNA-injected embryos contained at least 9 mismatches with the *Chd2* crRNA, 3) 2 of the 3 SNVs in Cas9 + crRNA-injected embryos were adjacent to non-canonical NAG PAM sequences, 4) the third SNV in a Cas9 + crRNA-injected embryo had 3 mismatches at the positions immediately adjacent to the PAM. All sequencing data was deposited in the NCBI Sequence Read Archive (SRA) under project accession PRJNA614534.

**Dual DNA-FISH/Immunocytochemistry:** Late S/G2 stage zygotes were used for immunocytochemistry as described above. Zygotes were stained with primary antibody (Rb anti-RAD51, Abcam, ab63801, 1:100) followed by tyramide signal amplification (Biotin XX Tyramide SuperBoost Kit, goat anti-rabbit IgG (ThermoFisher, B40921) and streptavidin, Alexa Fluor 488 Conjugate (ThermoFisher, S32354)) according to manufacturer's instructions. Zygotes were fixed again with 4% PFA, and processed for FISH as previously described (Nakaya et al., 2017). Zygotes were mounted in EASI-FISH chambers (poly-L-lysine hydrobromide (Sigma P1399)-coated coverslip (VWR 48393–106) mounted with double-layered clear patches (KOKUYO TA-3N) and fixed with 4% PFA. EASI-FISH chambers were treated with 0.5% saponin/0.5% TritonX-100 in PBS (PBST) for 30 minutes to permeabilize cells, incubated in 20% glycerol at room temperature in PBS for 30 minutes, and transferred to 50% glycerol in PBS before storing at  $-20^{\circ}\text{C}$  overnight. The chambers were then frozen in liquid nitrogen for 30 seconds followed by freezing-thawing in 20% glycerol five times. They were then washed in PBS, fixed with 4% PFA, incubated in 0.1N HCl for 10 minutes, washed with PBS, fixed with 4% PFA, incubated with PBST for 1 hour, fixed with 4% PFA, washed in 2x SSC, and incubated in 2X SSC/50% formamide until hybridization. FISH probe was prepared as previously described (Inoue et al., 2017, 2018). Briefly, Cy3-labeled FISH probe was prepared from a BAC clone containing the *Chd2* locus (BACPAC, clone RP24–290C18) using the Nick Translation Reagent Kit (Abbott Molecular 07J00–001) with Cy3-dCTP (GE Healthcare PA53021) according to manufacturer's instructions. The Cy3-labeled probe was then ethanol-precipitated with 10 $\mu\text{g}$  of Mouse Cot-1 DNA (ThermoFisher 18440–016) using GlycoBlue (ThermoFisher AM9515), and dissolved in 50% formamide/10% dextran sulfate/2X SSC. The probe mixture was heat denatured at  $80.5^{\circ}\text{C}$  for 4 minutes, cooled on ice, and applied to the EASI-FISH chamber. The EASI-FISH chamber was then heat denatured at  $80.5^{\circ}\text{C}$  for 4 minutes and then incubated at  $37^{\circ}\text{C}$  for at least for 5 days. After hybridization, the EASI-FISH chamber was washed once in 2X SSC, followed by three times in 0.1X SSC at  $62.5^{\circ}\text{C}$  for 5 minutes once in 4X SSC with 0.2% Tween20 (SSCT). The chamber was then subjected to immunocytochemistry a second time as described above, mounted with Fluoromount-G with DAPI (ThermoFisher 00–4959-52), and imaged and analyzed as described above.

**Embryonic Tissue Collection and DNA Purification:** After pronuclear injection, zygotes were cultured overnight and two-cell embryos were transferred to pseudopregnant CD-1 females as described above. Embryos were allowed to develop *in utero* for 9 days before pregnant females were sacrificed. Embryos were microdissected into cold, sterile PBS and washed twice before transfer to UV-sterilized 1.5mL snap-cap tubes. Embryo DNA was then purified using the NucleoSpin Tissue Genomic DNA Purification Kit (Takara, Cat. No. 740952) according to manufacturer's instructions. Genomic DNA was eluted with sterile TE buffer and split into aliquots of either 10ng/ $\mu\text{L}$  or 100ng/ $\mu\text{L}$  for use in downstream applications and stored at  $-20^{\circ}\text{C}$ .

**TOPO Cloning and Screening of Individual Alleles:** Primers for TOPO cloning and sequencing of clones are described in Table S3. For TOPO cloning, 100ng of genomic DNA per sample was used as input for PCR using Phusion High-Fidelity DNA Polymerase (New England Biolabs, M0350) using the standard buffer according to the manufacturer's

instructions. Samples were then run on a 1.5% agarose gel and, after confirming the presence of a single band, the target band was gel-purified using the ZymoClean Gel DNA Recovery Kit (Zymo Research, D4007). Products were eluted with 8 $\mu$ L of elution buffer and 4 $\mu$ L of the eluate was used as input for TOPO cloning with the Zero Blunt TOPO PCR Cloning Kit (ThermoFisher, K280020) according to the manufacturer's instructions. After transformation and plating, colonies were screened by colony PCR using the M13F/R primer pair. Colonies positive for the insert were then grown overnight and plasmids were purified using the ZymoPure Plasmid Miniprep Kit (Zymo Research, D4208) according to the manufacturer's instructions. Plasmids were then sequenced and sequences were aligned and analyzed using SnapGene (GSL Biotech).

## QUANTIFICATION AND STATISTICAL ANALYSIS

For all experiments testing homozygosity rates and rates of interhomolog repair a one-sided Fisher's exact test was used. Because we found in Figure 1 that RAD51 appeared to increase homozygosity and thus interhomolog repair, we explicitly tested this hypothesis and this was our justification for using a one-sided analysis.

For the qPCR experiments described in Figure 3D a two-sided Student's t-test was utilized.

For the correlation analysis in Figure S3B, we performed a simple linear regression and calculated Pearson's correlation coefficient.

For the calculation of mosaicism rates in Figure S4C, we utilized as a two-sided Fisher's exact test, as we did not have a predetermined expectation of the effects of the given enhancers on mosaicism.

All statistical analyses were performed using Prism 8 (GraphPad). All graphs display mean  $\pm$ SEM. \* $p$ <0.05, \*\* $p$ <0.01, \*\*\* $p$ <0.001, \*\*\*\* $p$ <0.0001

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgements

The experiments described in this manuscript were funded by the Hock E. Tan and K. Lisa Yang Center for Autism Research at MIT, the Poitras Center for Affective Disorders Research at MIT, NIH/NIMH Conte Center Grant (P50 MH094271) and NIH Office of the Director (U24 OD026638). We would like to thank Yuanyuan Hou (MIT) for technical assistance, Tetsushi Sakuma and Takashi Yamamoto (Hiroshima University) for sharing their knock-in enhancer screening data, Masataka Nakaya (Shiga Medical University), Hideyuki Tanabe (SOKENDAI), Zhiyuan Chen (Boston Children's Hospital), Yi Zhang (Boston Children's Hospital), and Azusa Inoue (RIKEN) for instruction and sharing protocols and materials for embryo FISH experiments, The Genomics platform at The Broad Institute of MIT and Harvard, Xian Adiconis (Broad Institute) and Yinqing Li (Tsinghua University) for helping with NGS experiments, and Hui Yang, Erwei Zuo, and Yidi Sun (Institute of Neuroscience) for additional instructions for GOTI experiments. Finally, we are grateful for the helpful discussions and valuable insights provided by Charles Jennings, Sabbi Lall, and members of the Feng lab.

## References

- Adikusuma F, Piltz S, Corbett MA, Turvey M, McColl SR, Helbig KJ, Beard MR, Hughes J, Pomerantz RT, and Thomas PQ (2018). Large deletions induced by Cas9 cleavage. *Nature* 560, E8–E9. [PubMed: 30089922]
- Aida T, Chiyo K, Usami T, Ishikubo H, Imahashi R, Wada Y, Tanaka KF, Sakuma T, Yamamoto T, and Tanaka K (2015). Cloning-free CRISPR/Cas system facilitates functional cassette knock-in in mice. *Genome Biol* 16, 87. [PubMed: 25924609]
- Aida T, Nakade S, Sakuma T, Izu Y, Oishi A, Mochida K, Ishikubo H, Usami T, Aizawa H, Yamamoto T, et al. (2016). Gene cassette knock-in in mammalian cells and zygotes by enhanced MMEJ. *BMC Genomics* 17, 183. [PubMed: 26939779]
- Bae S, Park J, and Kim J-S (2014). Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. *Bioinformatics* 30, 1473–1475. [PubMed: 24463181]
- Benjamin D, Sato T, Cibulskis K, Getz G, Stewart C, and Lichtenstein L (2019). Calling Somatic SNVs and Indels with Mutect2.
- Canny MD, Moatti N, Wan LCK, Fradet-Turcotte A, Krasner D, Mateos-Gomez PA, Zimmermann M, Orthwein A, Juang Y-C, Zhang W, et al. (2018). Inhibition of 53BP1 favors homology-dependent DNA repair and increases CRISPR-Cas9 genome-editing efficiency. *Nat. Biotechnol* 36, 95–102. [PubMed: 29176614]
- Caridi CP, Agostino C.D. x., Ryu T, Zapotoczny G, Delabaere L, Li X, Khodaverdian VY, Amaral N, Lin E, Rau AR, et al. (2018). Nuclear F-actin and myosins drive relocalization of heterochromatic breaks. *Nature* 559, 1–29.
- Charpentier M, Khedher AHY, Menoret S, Brion A, Lamribet K, Dardillac E, Boix C, Perrouault L, Tesson L, Geny S, et al. (2018). CtIP fusion to Cas9 enhances transgene integration by homology-dependent repair. *Nat. Commun* 9, 1133. [PubMed: 29556040]
- Chen J, Morrical MD, Donigan KA, Weidhaas JB, Sweasy JB, Averill AM, Tomczak JA, and Morrical SW (2015). Tumor-associated mutations in a conserved structural motif alter physical and biochemical properties of human RAD51 recombinase. *Nucleic Acids Res* 43, 1098–1111. [PubMed: 25539919]
- Concordet J-P, and Haeussler M (2018). CRISPOR: intuitive guide selection for CRISPR/Cas9 genome editing experiments and screens. *Nucleic Acids Res* 46, W242–W245. [PubMed: 29762716]
- Critchlow SE, Bowater RP, and Jackson SP (1997). Mammalian DNA double-strand break repair protein XRCC4 interacts with DNA ligase IV. *Curr. Biol* 7, 588–598. [PubMed: 9259561]
- Cukras S, Lee E, Palumbo E, Benavidez P, Moldovan G-L, and Kee Y (2016). The USP1-UAF1 complex interacts with RAD51AP1 to promote homologous recombination repair. *Cell Cycle* 15, 2636–2646. [PubMed: 27463890]
- D’Andrea AD, and Grompe M (2003). The Fanconi anaemia/BRCA pathway. *Nat. Rev. Cancer* 3, 23–34. [PubMed: 12509764]
- Deng Q, Ramsköld D, Reinius B, and Sandberg R (2014). Single-cell RNA-seq reveals dynamic, random monoallelic gene expression in mammalian cells. *Science* 343, 193–196. [PubMed: 24408435]
- Donoho G, Jasin M, and Berg P (1998). Analysis of gene targeting and intrachromosomal homologous recombination stimulated by genomic double-strand breaks in mouse embryonic stem cells. *Mol. Cell. Biol* 18, 4070–4078. [PubMed: 9632791]
- Dutta A, Eckelmann B, Adhikari S, Ahmed KM, Sengupta S, Pandey A, Hegde PM, Tsai M-S, Tainer JA, Weinfeld M, et al. (2017). Microhomology-mediated end joining is activated in irradiated human cells due to phosphorylation-dependent formation of the XRCC1 repair complex. *Nucleic Acids Res* 45, 2585–2599. [PubMed: 27994036]
- Egli D, Zuccaro MV, Kosicki M, Church GM, Bradley A, and Jasin M (2018). Inter-homologue repair in fertilized human eggs? *Nature* 560, E5–E7. [PubMed: 30089924]
- Ertl HA, Russo DP, Srivastava N, Brooks JT, Dao TN, and LaRocque JR (2017). The Role of Blm Helicase in Homologous Recombination, Gene Conversion Tract Length, and Recombination

Between Diverged Sequences in *Drosophila melanogaster*. *Genetics* 207, 923–933. [PubMed: 28912341]

- Fang H, Bergmann EA, Arora K, Vacic V, Zody MC, Iossifov I, O'Rawe JA, Wu Y, Jimenez Barron LT, Rosenbaum J, et al. (2016). Indel variant analysis of short-read sequencing data with Scalpel. *Nat. Protoc.* 11, 2529–2548. [PubMed: 27854363]
- Ghodsinejad Kalahroudi V, Kamalidehghan B, Arasteh Kani A, Aryani O, Tondar M, Ahmadipour F, Chung LY, and Houshmand M (2014). Two Novel Tyrosinase (TYR) Gene Mutations with Pathogenic Impact on Oculocutaneous Albinism Type 1 (OCA1). *PLoS One* 9, e106656. [PubMed: 25216246]
- Inoue A, Jiang L, Lu F, and Zhang Y (2017). Genomic imprinting of Xist by maternal H3K27me3. *Genes Dev* 31, 1927–1932. [PubMed: 29089420]
- Inoue A, Chen Z, Yin Q, and Zhang Y (2018). Maternal Eed knockout causes loss of H3K27me3 imprinting and random X inactivation in the extraembryonic cells. *Genes Dev* 32, 1525–1536. [PubMed: 30463900]
- Javidi-Parsijani P, Lyu P, Makani V, Sarhan WM, Yoo KW, El-Korashi L, Atala A, and Lu B (2020). CRISPR/Cas9 increases mitotic gene conversion in human cells. *Gene Ther*
- Jayavaradhan R, Pillis DM, Goodman M, Zhang F, Zhang Y, Andreassen PR, and Malik P (2019). CRISPR-Cas9 fusion to dominant-negative 53BP1 enhances HDR and inhibits NHEJ specifically at Cas9 target sites. *Nat. Commun* 10, 2866. [PubMed: 31253785]
- Kelso AA, Goodson SD, Watts LE, Ledford LL, Waldvogel SM, Diehl JN, Shah SB, Say AF, White JD, and Sehorn MG (2017). The  $\beta$ -isoform of BCCIP promotes ADP release from the RAD51 presynaptic filament and enhances homologous DNA pairing. *Nucleic Acids Res* 45, 711–725. [PubMed: 27694622]
- Kim S, Scheffler K, Halpern AL, Bekritsky MA, Noh E, Källberg M, Chen X, Kim Y, Beyter D, Krusche P, et al. (2018). Strelka2: fast and accurate calling of germline and somatic variants. *Nat. Methods* 15, 591–594. [PubMed: 30013048]
- Kosicki M, Tomberg K, and Bradley A (2018). Repair of double-strand breaks induced by CRISPR–Cas9 leads to large deletions and complex rearrangements. *Nat. Biotechnol* 1–10. [PubMed: 29251732]
- Krejčí L, Altmannova V, Špírek M, and Zhao X (2012). Homologous recombination and its regulation. *Nucleic Acids Res* 40, 5795–5818. [PubMed: 22467216]
- Ladstätter S, and Tachibana-Konwalski K (2016). A Surveillance Mechanism Ensures Repair of DNA Lesions during Zygotic Reprogramming. *Cell* 167, 1774–1787.e13. [PubMed: 27916276]
- LaRocque JR, Stark JM, Oh J, Bojilova E, Yusa K, Horie K, Takeda J, and Jasin M (2011). Interhomolog recombination and loss of heterozygosity in wild-type and Bloom syndrome helicase (BLM)-deficient mammalian cells. *Proc. Natl. Acad. Sci. U. S. A* 108, 11971–11976. [PubMed: 21730139]
- Li R, Bitoun E, Altemose N, Davies RW, Davies B, and Myers SR (2019). A high-resolution map of non-crossover events reveals impacts of genetic diversity on mammalian meiotic recombination. *Nat. Commun* 10, 3900. [PubMed: 31467277]
- Li Y, Lopez-Huerta VG, Adiconis X, Levandowski K, Choi S, Simmons SK, Arias-Garcia MA, Guo B, Yao AY, Blosser TR, et al. (2020). Distinct subnetworks of the thalamic reticular nucleus. *Nature* 583, 819–824. [PubMed: 32699411]
- Liang F, Longerich S, Miller AS, Tang C, Buzovetsky O, Xiong Y, Maranon DG, Wiese C, Kupfer GM, and Sung P (2016). Promotion of RAD51-Mediated Homologous DNA Pairing by the RAD51API-UAF1 Complex. *Cell Rep* 15, 2118–2126. [PubMed: 27239033]
- Liang P, Xu Y, Zhang X, Ding C, Huang R, Zhang Z, Lv J, Xie X, Chen Y, Li Y, et al. (2015). CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. *Protein Cell* 6, 363–372. [PubMed: 25894090]
- Liskay RM, and Stachelek JL (1986). Information transfer between duplicated chromosomal sequences in mammalian cells involves contiguous regions of DNA. *Proc. Natl. Acad. Sci. U. S. A* 83, 1802–1806. [PubMed: 3006074]




- Lu H, Guo X, Meng X, Liu J, Allen C, Wray J, Nickoloff JA, and Shen Z (2005). The BRCA2-Interacting Protein BCCIP Functions in RAD51 and BRCA2 Focus Formation and Homologous Recombinational Repair. *Mol. Cell. Biol* 25, 1949–1957. [PubMed: 15713648]
- Ma H, Marti-Gutierrez N, Park S-W, Wu J, Lee Y, Suzuki K, Koski A, Ji D, Hayama T, Ahmed R, et al. (2017). Correction of a pathogenic gene mutation in human embryos. *Nature* 548, 413–419. [PubMed: 28783728]
- Mansai SP, Kado T, and Innan H (2011). The Rate and Tract Length of Gene Conversion between Duplicated Genes. *Genes* 2, 313–331. [PubMed: 24710193]
- Marsden CG, Jensen RB, Zigelbaum J, Rothenberg E, Morrical SW, Wallace SS, and Sweasy JB (2016). The Tumor-Associated Variant RAD51 G151D Induces a Hyper-Recombination Phenotype. *PLoS Genet* 12, e1006208. [PubMed: 27513445]
- Maruyama T, Dougan SK, Truttmann MC, Bilate AM, Ingram JR, and Ploegh HL (2015). Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. *Nat. Biotechnol* 33, 538–542. [PubMed: 25798939]
- McVey M, and Lee SE (2008). MMEJ repair of double-strand breaks (director’s cut): deleted sequences and alternative endings. *Trends Genet* 24, 529–538. [PubMed: 18809224]
- Miele E, Mastronuzzi A, Po A, Carai A, Alfano V, Serra A, Colafati GS, Strocchio L, Antonelli M, Buttarelli FR, et al. (2015). Characterization of medulloblastoma in Fanconi Anemia: a novel mutation in the BRCA2 gene and SHH molecular subgroup. *Biomarker Research* 3, 13. [PubMed: 26064523]
- Moldovan G-L, and D’Andrea AD (2009). How the fanconi anemia pathway guards the genome. *Annu. Rev. Genet* 43, 223–249. [PubMed: 19686080]
- Moynahan ME, and Jasin M (1997). Loss of heterozygosity induced by a chromosomal double-strand break. *Proc. Natl. Acad. Sci. U. S. A* 94, 8988–8993. [PubMed: 9256422]
- Murai J, Yang K, Dejsuphong D, Hirota K, Takeda S, and D’Andrea AD (2011). The USP1/UAF1 complex promotes double-strand break repair through homologous recombination. *Mol. Cell. Biol* 31, 2462–2469. [PubMed: 21482670]
- Nakade S, Mochida K, Kunii A, Nakamae K, Aida T, Tanaka K, Sakamoto N, Sakuma T, and Yamamoto T (2018). Biased genome editing using the local accumulation of DSB repair molecules system. *Nat. Commun* 9, 3270. [PubMed: 30115916]
- Nakaya M, Tanabe H, Takamatsu S, Hosokawa M, and Mitani T (2017). Visualization of the spatial arrangement of nuclear organization using three-dimensional fluorescence in situ hybridization in early mouse embryos: A new “EASI-FISH chamber glass” for mammalian embryos. *J. Reprod. Dev* 63, 167–174. [PubMed: 28190810]
- Neuwirth EAH, Honma M, and Grosovsky AJ (2007). Interchromosomal crossover in human cells is associated with long gene conversion tracts. *Mol. Cell. Biol* 27, 5261–5274. [PubMed: 17515608]
- Normanno D, Négrel A, de Melo AJ, Betzi S, Meek K, and Modesti M (2017). Mutational phosphomimicry reveals a regulatory role for the XRCC4 and XLF C-terminal tails in modulating DNA bridging during classical non-homologous end joining. *Elife* 6, 1093.
- Oshidari R, Strecker J, Chung DKC, Abraham KJ, Chan JNY, Damaren CJ, and Mekhail K (2018). Nuclear microtubule filaments mediate non-linear directional motion of chromatin and promote DNA repair. *Nat. Commun* 9, 2567. [PubMed: 29967403]
- Paquet D, Kwart D, Chen A, Sproul A, Jacob S, Teo S, Olsen KM, Gregg A, Noggle S, and Tessier-Lavigne M (2016). Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9. *Nature* 533, 125–129. [PubMed: 27120160]
- Quadros RM, Miura H, Harms DW, Akatsuka H, Sato T, Aida T, Redder R, Richardson GP, Inagaki Y, Sakai D, et al. (2017). Easi-CRISPR: a robust method for one-step generation of mice carrying conditional and insertion alleles using long ssDNA donors and CRISPR ribonucleoproteins. *Genome Biol* 18, 103. [PubMed: 28569170]
- Rees HA, Yeh W-H, and Liu DR (2019). Development of hRad51-Cas9 nickase fusions that mediate HDR without double-stranded breaks. *Nat. Commun* 10, 2212. [PubMed: 31101808]
- Reichmann J, Nijmeijer B, Hossain MJ, Eguren M, Schneider I, Politi AZ, Roberti MJ, Hufnagel L, Hiiragi T, and Ellenberg J (2018). Dual-spindle formation in zygotes keeps parental genomes apart in early mammalian embryos. *Science* 361, 189–193. [PubMed: 30002254]



- Richardson C, Moynahan ME, and Jasin M (1998). Double-strand break repair by interchromosomal recombination: suppression of chromosomal translocations. *Genes Dev* 12, 3831–3842. [PubMed: 9869637]
- Richardson CD, Kazane KR, Feng SJ, Zelin E, Bray NL, Schäfer AJ, Floor SN, and Corn JE (2018). CRISPR-Cas9 genome editing in human cells occurs via the Fanconi anemia pathway. *Nat. Genet* 50, 1132–1139. [PubMed: 30054595]
- Ruk A, Bell-Rogers PL, Smith JDL, and Baker MD (2008). Analysis of spontaneous gene conversion tracts within and between mammalian chromosomes. *J. Mol. Biol* 377, 337–351. [PubMed: 18262541]
- Santos F, Peat J, Burgess H, Rada C, Reik W, and Dean W (2013). Active demethylation in mouse zygotes involves cytosine deamination and base excision repair. *Epigenetics Chromatin* 6, 39. [PubMed: 24279473]
- Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, et al. (2012). Fiji: an open-source platform for biological-image analysis. *Nat. Methods* 9, 676–682. [PubMed: 22743772]
- Shin HY, Wang C, Lee HK, Yoo KH, Zeng X, Kuhns T, Yang CM, Mohr T, Liu C, and Hennighausen L (2017). CRISPR/Cas9 targeting events cause complex deletions and insertions at 17 sites in the mouse genome. *Nat. Commun* 8, 15464. [PubMed: 28561021]
- Smith JA, Bannister LA, Bhattacharjee V, Wang Y, Waldman BC, and Waldman AS (2007). Accurate homologous recombination is a prominent double-strand break repair pathway in mammalian chromosomes and is modulated by mismatch repair protein Msh2. *Mol. Cell. Biol* 27, 7816–7827. [PubMed: 17846123]
- Song J, Yang D, Xu J, Zhu T, Chen YE, and Zhang J (2016). RS-1 enhances CRISPR/Cas9- and TALEN-mediated knock-in efficiency. *Nat. Commun* 7, 10548. [PubMed: 26817820]
- Stark JM, and Jasin M (2003a). Extensive loss of heterozygosity is suppressed during homologous repair of chromosomal breaks. *Mol. Cell. Biol* 23, 733–743. [PubMed: 12509470]
- Stark JM, and Jasin M (2003b). Extensive loss of heterozygosity is suppressed during homologous repair of chromosomal breaks. *Mol. Cell. Biol* 23, 733–743. [PubMed: 12509470]
- Takayama K, Igai K, Hagihara Y, Hashimoto R, Hanawa M, Sakuma T, Tachibana M, Sakurai F, Yamamoto T, and Mizuguchi H (2017). Highly efficient biallelic genome editing of human ES/iPS cells using a CRISPR/Cas9 or TALEN system. *Nucleic Acids Res* 45, 5198–5207. [PubMed: 28334759]
- Taylor RM, Moore DJ, Whitehouse J, Johnson P, and Caldecott KW (2000). A cell cycle-specific requirement for the XRCC1 BRCT II domain during mammalian DNA strand break repair. *Mol. Cell. Biol* 20, 735–740. [PubMed: 10611252]
- Tran N-T, Bashir S, Li X, Rossius J, Chu VT, Rajewsky K, and Kühn R (2019). Enhancement of Precise Gene Editing by the Association of Cas9 With Homologous Recombination Factors. *Front. Genet* 10, 365. [PubMed: 31114605]
- van Twest S, Murphy VJ, Hodson C, Tan W, Swuec P, O'Rourke JJ, Heierhorst J, Crismani W, and Deans AJ (2017). Mechanism of Ubiquitination and Deubiquitination in the Fanconi Anemia Pathway. *Mol. Cell* 65, 247–259. [PubMed: 27986371]
- Wang AT, Kim T, Wagner JE, Conti BA, Lach FP, Huang AL, Molina H, Sanborn EM, Zierhut H, Cornes BK, et al. (2015). A Dominant Mutation in Human RAD51 Reveals Its Function in DNA Interstrand Crosslink Repair Independent of Homologous Recombination. *Mol. Cell* 59, 478–490. [PubMed: 26253028]
- Wang K, Li M, and Hakonarson H (2010). ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res* 38, e164. [PubMed: 20601685]
- Wilde JJ, Siegenthaler JA, Dent SYR, and Niswander LA (2017). Diencephalic Size is Restricted by a Novel Interplay Between GCN5 Acetyltransferase Activity and Retinoic Acid Signaling. *Journal of Neuroscience* 37, 2121–16 – 50.
- Wilm A, Aw PPK, Bertrand D, Yeo GHT, Ong SH, Wong CH, Khor CC, Petric R, Hibberd ML, and Nagarajan N (2012). LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets. *Nucleic Acids Res* 40, 11189–11201. [PubMed: 23066108]


- Wray J, Liu J, Nickoloff JA, and Shen Z (2008). Distinct RAD51 Associations with RAD52 and BCCIP in Response to DNA Damage and Replication Stress. *Cancer Res* 68, 2699–2707. [PubMed: 18413737]
- Wu Y, Liang D, Wang Y, Bai M, Tang W, Bao S, Yan Z, Li D, and Li J (2013). Correction of a Genetic Disease in Mouse via Use of CRISPR-Cas9. *Cell Stem Cell* 13, 659–662. [PubMed: 24315440]
- Yang K, Moldovan GL, Vinciguerra P, Murai J, Takeda S, and D'Andrea AD (2011). Regulation of the Fanconi anemia pathway by a SUMO-like delivery network. *Genes Dev* 25, 1847–1858. [PubMed: 21896657]
- Yu DS, Sonoda E, Takeda S, Huang CLH, Pellegrini L, Blundell TL, and Venkitaraman AR (2003). Dynamic control of Rad51 recombinase by self-association and interaction with BRCA2. *Mol. Cell* 12, 1029–1041. [PubMed: 14580352]
- Yusa K, Horie K, Kondoh G, Kouno M, Maeda Y, Kinoshita T, and Takeda J (2004). Genome-wide phenotype analysis in ES cells by regulated disruption of Bloom's syndrome gene. *Nature* 429, 896–899. [PubMed: 15215867]
- Zadorozhny K, Sannino V, Belá O, Mi oušková J, Špírek M, Costanzo V, and Krej í L (2017). Fanconi-Anemia-Associated Mutations Destabilize RAD51 Filaments and Impair Replication Fork Protection. *Cell Rep* 21, 333–340. [PubMed: 29020621]
- Zuo E, Sun Y, Wei W, Yuan T, Ying W, Sun H, Yuan L, Steinmetz LM, Li Y, and Yang H (2019). Cytosine base editor generates substantial off-target single-nucleotide variants in mouse embryos. *Science* 364, 289–292. [PubMed: 30819928]
- Zuo E, Sun Y, Wei W, Yuan T, Ying W, Sun H, Yuan L, Steinmetz LM, Li Y, and Yang H (2020). GOTI, a method to identify genome-wide off-target effects of genome editing in mouse embryos. *Nat. Protoc* 15, 3009–3029. [PubMed: 32796939]

- Interhomolog repair (IHR) occurs throughout the genome in the early mouse embryo
- RAD51, BCCIP, and USP1/WDR48 enhance IHR at sites of Cas9-induced DNA breaks
- Embryonic IHR occurs via gene conversion without crossover
- Enhanced IHR can be used for homozygous knock-in and donor-free allelic conversion




**Figure 1. Efficient homozygous knock-in with RAD51**

(A) Schematic of the targeted locus and HR donor for generating *Chd2*<sup>RH</sup> mutant mice. Donor contains both the c.5051G>A point mutation and a synonymous mutation in the relevant PAM site (HA=homology arm). (B) Example chromatograms of wildtype (top) and *Chd2*<sup>RH/RH</sup> animals (bottom). (C) Overall KI efficiency observed in F<sub>0</sub> pups derived from either cytoplasmic (CPI) or pronuclear (PNI) injection (pups with 1 KI allele/total pups). (D) Homozygous KI rates observed in F<sub>0</sub> pups generated by either CPI or PNI, shown as percentage of all pups or pups positive for KI. (E) Genotyping results from F<sub>1</sub> pups derived from crosses between F<sub>0</sub> *Chd2*<sup>RH/RH</sup> animals and wild-type animals.



**Figure 2. RAD51 enhances homozygous KI efficiency at multiple loci**

(A) Quantification of KI efficiency (left) and homozygous KI efficiency in embryos generated by *Chd2<sup>RH</sup>* PNI with or without RAD51. All *RH/RH* includes mosaic embryos and denotes embryos with 3:2 ratio of mutant allele to wildtype allele (one-sided Fisher’s exact test). (B) Schematic of knock-in strategy for the albinism-associated *Tyr<sup>C89S</sup>* mutation. (C) Representative examples of *Tyr<sup>+/+</sup>* (black) and *Tyr<sup>C89S/C89S</sup>* (white) littermates derived from injections using exogenous RAD51 protein. (D) Representative chromatograms from *Tyr<sup>+/+</sup>* (top) and *Tyr<sup>C89S/C89S</sup>* animals. (E) Genotyping of F<sub>0</sub> animals from injections targeting the *Tyr<sup>C89S</sup>* locus with or without RAD51 (one-sided Fisher’s exact test). \*p<0.05, \*\*\*p<0.001, n.s. p>0.05



**Figure 3. RAD51 enhances interhomolog repair.**

(A) Schematic of strategy for testing evaluating embryonic IHR. Wild-type oocytes were fertilized *in vitro* by sperm collected from *Chd2<sup>RH/RH</sup>* males and cultured for ~8 hours. PNI was then performed with Cas9 protein, tracrRNA, and crRNA specifically targeting the wild-type maternal allele. Injected embryos were then cultured for 2–3 days and collected at the morula or blastocyst stage. Half of the purified DNA was used for nested PCR and Sanger sequencing and the other half was used for multiplex PCR and subsequent qPCR to analyze genomic copy number at the *Chd2* editing locus. (B) Representative chromatograms showing the wild-type reference sequence (Ref., top), an uninjected *Chd2<sup>RH/+</sup>* embryo generated by IVF (Uninj., middle), and a pure *Chd2<sup>RH/RH</sup>* homozygous mutant (IHR, bottom) generated through IHR. (C) Quantification of Sanger sequencing results from IVF-derived embryos edited with or without RAD51. ‘All IHR’ includes mosaic embryos and was determined by identifying embryos with 3:2 ratio of R1684H allele to all other alleles (one-sided Fisher’s exact test). Pure IHR denotes embryos without mosaicism (p=0.018,




one-tailed chi-square test). **(D)** Genomic qPCR targeting the *Chd2<sup>RH</sup>* locus in embryos carrying a large heterozygous deletion (*Chd2<sup>del/+</sup>*) as a control for copy-number sensitivity (lanes 1–2, unpaired t-test,  $n=3$  embryos, error bars=SEM). Lanes 3–13 show genomic qPCR for the *Chd2<sup>RH</sup>* locus using DNA from an uninjected embryo and 10 randomly selected pure homozygous *Chd2<sup>RH</sup>* embryos ( $p>0.05$ , unpaired t-test,  $n=4$  technical replicates per sample, error bars=SEM). **(E)** F<sub>1</sub> genotyping results of litters derived from crosses between wild-type mice and 5 pure *Chd2<sup>RH/RH</sup>* F<sub>0</sub> animals generated by the strategy described in (A), including RAD51. \* $p<0.05$ , \*\* $p<0.01$ , \*\*\* $p<0.0001$

Author Manuscript

Author Manuscript


Author Manuscript

Author Manuscript




**Figure 4. RAD51 Localizes to Cas9-Induced DSBs During G2 in Zygotes.**


(A) Representative images of RAD51 immunocytochemistry in G1/S, S/G2, and M-phase zygotes injected with Cas9 and RAD51. Arrowheads indicate RAD51 puncta. Dotted lines highlight pronuclear nucleoli. (Scale bar=10µm) (B) Quantification of zygotes positive for RAD51 puncta (one-sided Fisher’s exact test). \*\*\*p<0.001, \*\*\*\*p<0.0001, n.s. p>0.05



**Figure 5. RAD51 Enhances Interhomolog Repair at Loci on Multiple Chromosomes.** (A-C) Genotyping of embryos at the *Mecip2*, *Acs16*, and *Kcnb2* loci. Representative chromatograms of unedited and pure IHR embryos shown below graphs. Red letters denote SNVs and underlined bases represent deletions. All IHR denotes embryos with 3:2 ratio of the IHR allele to all other alleles. Pure IHR denotes non-mosaic IHR (one-sided Fisher’s exact test). \*p<0.05, \*\*p<0.01



**Figure 6. RAD51 G151D and BCCIP promote zygotic IHR and suppress indel formation.** (A) Quantification of IHR efficiency in blastocysts derived *Chd2<sup>RH/+</sup>* zygotes injected with Cas9/crRNA/tracrRNA and the indicated proteins. Quantification includes mosaic embryos (one-sided Fisher’s exact test). (B) Quantification of IHR efficiency in blastocysts derived *Chd2<sup>RH/+</sup>* zygotes injected with Cas9/crRNA/tracrRNA and the indicated RAD51 variants (one-sided Fisher’s exact test). (C) Quantification of editing efficiency at the *Chd2<sup>RH</sup>* locus in embryos injected with Cas9/crRNA/tracrRNA and the indicated RAD51 variants (one-sided Fisher’s exact test). (D) *In vitro* Cas9 nuclease activity assay using a PCR amplicon of the *Chd2<sup>RH</sup>* locus and Cas9 alone or co-incubated with either RAD51 G151D or BCCIP. (E) Quantification of the percent of total injected embryos carrying an indel after injection with the specified proteins (one-sided Fisher’s exact test). (F) Quantification of the ratio of indel-positive embryos to IHR-positive embryos derived from injections with the specified proteins (one-sided Fisher’s exact test). \*p<0.05, \*\*p<0.01, \*\*\*\*p<0.0001



**Figure 7. IHR Induces Conversion of Long Recombination Tracts.**

(A) Schematic of genotyping strategies for *Acs16* and *Kcnb2* loci. Black arrows denote locations of primers for local PCR of SNPs tiled across regions. Red arrows denote locations of primers for long-range PCR and TOPO cloning. Vertical lines denote approximate locations of SNPs. (B) Summary of genotyping results from local PCR of tiled SNPs. Pink boxes denote homozygous A/J alleles and mixed-color boxes denote heterozygous alleles with A/J and C57BL/6J SNPs. (C) Summary of genotyping results from TOPO cloning of long-range PCR products. Mixed-color boxes are used for any sites with at least one clone of

the indicated allele. Asterisks denote embryos with low level of an allele, indicating mosaicism (see also Figure S5).

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript